Innovent Bio hopes for plus-sized profits from obesity drug
信达生物维持营收目标 重点布局心血管代谢药

The biopharmaceutical company reported a surge in half-year revenues but logged a bigger net loss, as investors look ahead to the launch of its new weight-loss drug.
这家生物药制造商上半年总收入增加46.3%，其中药品销售带来的产品收入达38.11亿元，同比大增55.1%。